Esperion Therapeutics | ESPR - Cash And Equivalent


Esperion Therapeutics reported $156.16M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
AbbVie USD 9.39B 4.16B Mar/2026
Alnylam Pharmaceuticals USD 1.71B 53.53M Mar/2026
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Amarin USD 131.06M 3.6M Mar/2026
Amgen USD 12.04B 2.91B Mar/2026
Biogen USD 3.38B 374.2M Mar/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Cipla INR 7.96B 39.9M Sep/2025
CSL USD 2.16B 633M Jun/2025
Cytokinetics USD 129.84M 7.32M Mar/2026
Daiichi Sankyo JPY 542.16B 97.68B Sep/2025
Eli Lilly USD 5.28B 1.99B Mar/2026
Esperion Therapeutics USD 156.16M 11.69M Mar/2026
Geron USD 68.9M 10.54M Mar/2026
Grifols EUR 979.78M 334.84M Dec/2024
Halozyme Therapeutics USD 309.75M 175.93M Mar/2026
Heron Therapeutics USD 26.12M 2.53M Mar/2026
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Moderna USD 1.91B 687M Mar/2026
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Pfizer USD 1.7B 561M Mar/2026
PTC Therapeutics USD 833.99M 150.66M Mar/2026
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Regeneron Pharmaceuticals USD 2.96B 15.9B Mar/2026
Sanofi EUR 7.66B 1.25B Dec/2025
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026
United Therapeutics USD 1.28B 277.4M Mar/2026
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025